Officials urge those who left school without lifesaving vaccine to get protected
It comes amid warnings that more than 418,000 children have left school with no protection against human papillomavirus (HPV) in the last three years.
The HPV vaccine is offered to boys and girls when they are in Year 8 and is key to wiping out cervical cancer in the UK.
Around 13 high-risk types of HPV are known to cause 99.7% of cervical cancers.
The jab also protects against genital warts and head and neck cancers, such as those in the mouth or throat.
Now, GP practices in England will invite 16 to 25-year-olds to have the vaccine if records show they did not have it in school.
According to NHS England, more than 418,000 children left school without having the jab in the last three years, with concerns there are many more people aged 16 to 25 who are not protected.
Dr Amanda Doyle, national director of primary care and community services, said: 'This vaccine is hugely important in our fight to eradicate cervical cancer but it isn't just for girls and women – it's also vital for boys and men to get vaccinated to protect themselves against cancers of the mouth, throat or genitals, while preventing spreading the HPV infection to sexual partners who could then develop cervical cancer.
'Too many lives are lost to cervical cancer so the hard work of NHS staff across the country in vaccinating and screening as many people as possible will help us to meet our ambition of wiping out this disease.
'Encouraging progress has been made recently in increasing uptake but we know there is much more to do.
'So if you're eligible for a HPV vaccination or are the parent of a child who is eligible, but didn't get the vaccine at school when they had the chance, I would urge you to come forward when your GP contacts you.
'Only a single dose is required and it could save you or your child's life.'
Data shows that in the 2023/24 academic year, some 76.7% of girls and 71.2% of boys aged 14 to 15 were vaccinated against HPV by Year 10.
Uptake in Year 8 increased to 72.9% among girls and 67.7% among boys, from 71.3% and 65.2% respectively a year earlier.
The health service will aim to boost uptake among girls to 90% as part of plans to eliminate cervical cancer by 2040.
It will also aim to increase the number of women attending cervical cancer screening appointments.
Public health minister Ashley Dalton said the vaccine 'is our most powerful tool in our fight to eliminate cervical cancer by 2040' but said there is a 'long way to go'.
'Thousands of young people are still unvaccinated and vulnerable to this disease – which is so easily prevented,' she added.
Last month, the UK Health Security Agency (UKHSA) warned young women in some parts of England are at greater risk of cervical cancer because not enough children are getting the jab.
Analysis by the agency showed inequalities in vaccine uptake in some regions – by Year 10, HPV coverage in girls was lowest in London (64.9%) and highest in the South East (82.7%).
Among boys, it was also lowest in London (58.9%) and highest in the South East (77.3%).
Meanwhile, at local authority level, Year 10 vaccination levels in girls ranged from 38.7% (Lambeth in London) to 97.6% (Northumberland).
Among boys, it ranged from 28.2% (Lambeth in London) to 92.2% (West Berkshire).
Dr Sharif Ismail, consultant epidemiologist at UKHSA, said: 'We know that uptake of the HPV vaccination in young people has fallen significantly since the pandemic, leaving many, many thousands across the country at greater risk of HPV-related cancers.
'This is a real concern as each HPV vaccine, now just a single dose offered in schools, gives a young person good protection against the devastating impact of these cancers, which includes cervical, genital, mouth and throat cancers.
'This new catch-up campaign is a really important opportunity for us to make sure that no teenage girl or boy, young woman or man is denied that protection.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Billy Joel says he's 'OK' and not 'deathly ill' after receiving brain disorder diagnosis
NEW YORK (AP) — Billy Joel is doing much better, the 'Piano Man' singer wants fans to know. In May, Joel canceled all his upcoming concerts across North America and England after being diagnosed with fluid buildup in his brain that has affected his 'hearing, vision and balance.' The condition is called Normal Pressure Hydrocephalus, 'a brain disorder that can affect brain-related abilities, including thinking and concentrating, memory, movement and more,' the Cleveland Clinic says. 'I know a lot of people are worried about me and my health, but I'm OK,' Joel said in an interview with People magazine. "What I have is something very few people know about, including me, no matter how much you try to research it. I'm doing my best to work with it and to recover from it.' 'It was scary, but I'm OK,' Joel, 76, says. 'I just wanted to let people know, don't worry about me being deathly ill or anything.' He also discussed his health in an episode of comedian Bill Maher's Club Random podcast, telling the host he feels 'fine," adding that, 'My balance sucks. It's like being on a boat... They keep referring to what I have as a brain disorder, so it sounds a lot worse than what I'm feeling." He added that his health issues are not 'fixed,' but 'it's still being worked on.' A representative for Joel declined additional comment. In March, the 'Uptown Girl' singer announced that he underwent surgery and had to undergo physical therapy. A statement at the time said doctors expected him to make a full recovery. It is unclear if his medical issues at the time were related to Normal Pressure Hydrocephalus. The condition can cause problems with walking, bladder control and thinking, with symptoms worsening if left untreated. It's relatively rare and can be hard to diagnose. It can be treated successfully with surgery to install a tube to drain excess fluid. Patients may need physical therapy in addition to surgery. Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Major HRT supplier sanctioned after whistleblowers raise concerns over patient safety
A major UK supplier of menopause drug HRT has been sanctioned after whistleblowers claimed patients were being put at risk, it has emerged. A group of employees from Theramex, which supplies HRT treatments to millions of patients in the UK, wrote a letter to the pharmaceutical regulator Association of the British Pharmaceutical Industry over allegations the company was not following regulatory standards and may 'jeopardise' patient safety. The whistleblowers claimed some products featured inaccurate prescribing information and failed to highlight common side effects. They claimed they had been forced to contact the regulator after their attempts to raise issues internally were brushed off. The company has now admitted it breached regulatory codes, amounting to 'bringing discredit upon, and reducing confidence in the pharmaceutical industry', according to an interim case report from the ABPI. It also failed to maintain high standards and provide accurate and up-to-date prescribing information, the report said. Theramex is a global pharmaceutical company specialising in women's health products, such as hormone replacement therapy (HRT) and fertility treatments. Theramex UK is its London-based arm. It supplies common HRT therapies including Evorel, Bijuve and Intrarosa. From April to June 2025, there were 760,000 prescriptions of Evorel and 2,748 prescriptions of Bijuve, according to data from the NHS Business Services Authority. In 2023-24, there were 2.8 million prescriptions of Evorel. One employee wrote the complaint on behalf of a group, according to the complaint published by the Prescription Medicines Code of Practice Authority, which is part of the ABPI. The complaint, filed in October 2024, said: 'We are a group of employees from various cross-functional teams at Theramex, and we are writing to express our growing concerns regarding the company's adherence to regulatory standards and the accountability of its leadership. 'While we have attempted to escalate these issues internally on numerous occasions, there has been a consistent lack of action or meaningful response, which leaves us with no choice but to seek external guidance and support.' The complaint alleged that some of Theramex's products, such as Intrarosa and Evorel, had not had their prescribing information updated. In the case of Evorel, information for health professionals was 'incomplete' and did not include information on common side effects such as uterine spasms and vaginal infection, the letter claimed. For another drug, the letter alleged that prescribing information had not been updated for five years. The complaint warned: 'This oversight can lead to healthcare professionals (HCPs) not being fully informed of potential risks, which could jeopardise patient safety.' The PMCPA panel found Theramix's 'failure to provide accurate and complete prescribing information was unacceptable'. The employees also alleged the company failed to comply with regulators for clinical trial compliance warning. 'The lack of resources within Theramex's global headquarters to ensure compliance with these standards is alarming,' it said. Finally, the letter alleged the company has a 'blame culture' that was 'deeply concerning.' In response to the complaint, Theramex UK said it took its obligations under the ABPI code of practice 'very seriously' and launched an internal investigation. It said that, although it had a process to update prescribing information, this was not sufficiently robust to ensure prescribing information was immediately updated. The pharma company acknowledged it did not meet standards concerning this allegation and admitted that, at the time of the complaint, it did not have a process in place for clinical studies. The employees' letter claimed it had tried to escalate matters to senior leaders within Theramex. The company claimed it was not aware of any of the matters having been escalated internally prior to them being reported to the regulator. As part of the sanction, Theramex must provide written confirmation that it will cease practices that breach codes, pay a charge and advertise details of the case. Theramex UK said it 'absolutely acknowledges' the recent ruling and 'respects the [regulator's] decision'. 'Of course, we remain fully committed to ensuring our practices align with the highest ethical standards and necessary steps and corrective measures have been taken,' it said.
Medscape
an hour ago
- Medscape
Rapid Review: Cervical Cancer
Although often preventable, cervical cancer continues to be underdiagnosed in areas lacking access to routine Pap smears or human papillomavirus (HPV) testing. Screening, along with public health initiatives promoting HPV vaccination, are central to global elimination efforts. Advances in treatment— including minimally invasive surgery, targeted therapy, and immunotherapy — have also expanded options for individualized care. According to a recent comprehensive review and meta-analysis, AI-assisted colposcopy outperformed clinicians in all comparative measurements, including accuracy, sensitivity, specificity, positive predictive value, and negative predictive value. Specifically, AI assessment had an accuracy of 81% compared to 74% by clinicians, with the biggest difference seen in specificity where AI achieved 83% compared to 67%. AI also achieved high levels of accuracy when assessing pap smears, with an overall accuracy of 94%. Identification of these pathological changes are important; when high-risk HPV types persist, they can integrate into the host genome and trigger a series of molecular changes. These changes disrupt normal cell cycle regulation and can lead to the development of cervical intraepithelial neoplasia (CIN), which can progress from low-grade lesions to high-grade dysplasia and eventually invasive carcinoma if left untreated. Learn more about the presentation of cervical cancer. A recent cross-sectional analysis of the National Immunization Survey-Teen register found that 'safety concerns' was the most common reason for vaccine hesitancy among parents of adolescents eligible for the HPV vaccine, and that this has been an increasing trend throughout the past decade, rising from 17.5% in 2014 to 29.1% in 2020. In contrast, other reasons for vaccine hesitancy such as 'not necessary,' 'lack of knowledge,' and 'not sexually active' all saw a decreasing trend throughout this time. HPV vaccination disparities are most pronounced in adolescents from rural areas due to reduced access to healthcare and limited provider recommendation. HPV vaccination, particularly when administered before the onset of sexual activity, significantly reduces the risk of developing high-grade cervical lesions. Learn more about screening guidelines for cervical cancer. For average-risk women aged 30-65, the USPSTF recommends one of three screening strategies: cytology alone every 3 years, high-risk HPV testing alone every 5 years, or co-testing (cytology + HPV) every 5 years. Annual screening is not recommended due to lack of additional benefit and potential harms such as overtreatment. Colposcopy is a diagnostic procedure, not a screening method, and is not used routinely in women without abnormal screening results. Learn more about the workup for patients suspected of cervical cancer. Current HPV testing is more sensitive than cytology for detecting CIN, and cytology alone may miss some precancerous lesions that HPV testing would detect. In addition to greater sensitivity, HPV testing allows for longer screening intervals, which can reduce the burden of testing in patients unnecessary follow-up procedures. Learn more about approach considerations in patients with cervical cancer. The USPSTF recommends that routine cervical cancer screening be discontinued in women older than 65 years who are not at high risk and have had an adequate history of prior screening. Adequate prior screening is specifically defined as having either three consecutive negative cytology (Pap smear) results within the past 10 years or two consecutive negative high-risk human papillomavirus (hrHPV) tests within the same timeframe, with the most recent test conducted within the last 5 years. This guidance reflects the understanding that the risk of developing cervical cancer after age 65 is very low in women who have had regular negative screenings and no history of cervical precancer or cancer. However, it is important to note that women with a history of high-grade precancerous lesions (such as CIN2 or CIN3), cervical cancer, or those who have not been adequately screened should continue regular surveillance past age 65. This recommendation is part of a broader risk-based approach that aims to balance early detection with the potential harms of over-screening. Learn more about treatment options for patients once diagnosed with cervical cancer.
